+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Hemoglobinopathies Treatment Market 2019-2023 - Product Image

Global Hemoglobinopathies Treatment Market 2019-2023

  • ID: 4745563
  • Report
  • Region: Global
  • 113 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • ApoPharma
  • Bristol-Myers Squibb
  • Emmaus Medical
  • Medunik USA
  • Novartis
  • MORE
Development of gene therapy to drive growth in the market. The advances of regenerative medicines in the clinical phases are expected to fuel growth of the global hemoglobinopathies treatment market. Analysts have predicted that the hemoglobinopathies treatment market will register a CAGR of almost 11% by 2023.

Market Overview

Strong pipeline and expected approvals of late-stage molecule

The market is witnessing an acute lack of approved therapies, these late-stage pipeline molecules are expected to gain momentum during the forecast period, which will fuel the market growth.

Product recalls and tedious drug approval process

The strict regulations for providing the marketing approval for therapeutics that are being developed for the treatment of hemoglobinopathies is likely to pose a threat to the market.

For the detailed list of factors that will drive and challenge the growth of the hemoglobinopathies treatment market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Medunik USA and Novartis, the competitive environment is quite intense. Factors such as the strong pipeline and expected approvals of late-stage molecule and the development of gene therapy, will provide considerable growth opportunities to hemoglobinopathies treatment manufactures. ApoPharma, Bristol-Myers Squibb, Emmaus Medical, Medunik USA, and Novartis are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ApoPharma
  • Bristol-Myers Squibb
  • Emmaus Medical
  • Medunik USA
  • Novartis
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Sickle cell disease - Market size and forecast 2018-2023
  • Thalassemia - Market size and forecast 2018-2023
  • Market opportunity by type
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DRIVERS AND CHALLENGES

PART 10: VENDOR LANDSCAPE
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • ApoPharma
  • Bristol-Myers Squibb
  • Emmaus Medical
  • Medunik USA
  • Novartis
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global hematology drugs market
Exhibit 03: Segments of global hematology drugs market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Sickle cell disease - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Sickle cell disease - Year-over-year growth 2019-2023 (%)
Exhibit 22: Thalassemia - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Thalassemia - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in Americas
Exhibit 31: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in EMEA
Exhibit 34: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in APAC
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Decision framework
Exhibit 40: Therapeutics that have received the orphan drug designation from the US FDA recently
Exhibit 41: Impact of drivers and challenges
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: ApoPharma - Vendor overview
Exhibit 48: ApoPharma - Business segments
Exhibit 49: ApoPharma - Organizational developments
Exhibit 50: ApoPharma - Key offerings
Exhibit 51: ApoPharma - Key customers
Exhibit 52: Bristol-Myers Squibb - Vendor overview
Exhibit 53: Bristol-Myers Squibb - Business segments
Exhibit 54: Bristol-Myers Squibb - Organizational developments
Exhibit 55: Bristol-Myers Squibb - Geographic focus
Exhibit 56: Bristol-Myers Squibb - Key offerings
Exhibit 57: Bristol-Myers Squibb - Key customers
Exhibit 58: Emmaus Medical - Vendor overview
Exhibit 59: Emmaus Medical - Business segments
Exhibit 60: Emmaus Medical - Organizational developments
Exhibit 61: Emmaus Medical - Geographic focus
Exhibit 62: Emmaus Medical - Key offerings
Exhibit 63: Emmaus Medical - Key customers
Exhibit 64: Medunik USA - Vendor overview
Exhibit 65: Medunik USA - Business segments
Exhibit 66: Medunik USA - Organizational developments
Exhibit 67: Medunik USA - Key offerings
Exhibit 68: Medunik USA - Key customers
Exhibit 69: Novartis - Vendor overview
Exhibit 70: Novartis - Business segments
Exhibit 71: Novartis - Organizational developments
Exhibit 72: Novartis - Geographic focus
Exhibit 73: Novartis - Segment focus
Exhibit 74: Novartis - Key offerings
Exhibit 75: Novartis - Key customers
Exhibit 76: Validation techniques employed for market sizing
Exhibit 77: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • ApoPharma
  • Bristol-Myers Squibb
  • Emmaus Medical
  • Medunik USA
  • Novartis
  • MORE
Global Hemoglobinopathies Treatment Market 2019-2023

The analyst recognizes the following companies as the key players in the global hemoglobinopathies treatment market: ApoPharma, Bristol-Myers Squibb, Emmaus Medical, Medunik USA, and Novartis.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of gene therapy.”

According to the report, one of the major drivers for this market is the strong pipeline and expected approvals of late-stage molecule.

Further, the report states that one of the major factors hindering the growth of this market is the product recalls and tedious drug approval process.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • ApoPharma
  • Bristol-Myers Squibb
  • Emmaus Medical
  • Medunik USA
  • Novartis
Note: Product cover images may vary from those shown
Adroll
adroll